Next Article in Journal
Characterization of Somatic Embryogenesis Receptor-Like Kinase 4 as a Negative Regulator of Leaf Senescence in Arabidopsis
Next Article in Special Issue
Autophagy in Chronic Kidney Diseases
Previous Article in Journal
Nanobody Detection of Standard Fluorescent Proteins Enables Multi-Target DNA-PAINT with High Resolution and Minimal Displacement Errors
Previous Article in Special Issue
Relevance of Autophagy in Parenchymal and Non-Parenchymal Liver Cells for Health and Disease

Metformin Impairs Glutamine Metabolism and Autophagy in Tumour Cells

Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy
Department of Cellular and Molecular Pathology, IRCCS San Raffaele, 00166 Rome, Italy
MEBIC Consortium, San Raffaele Rome Open University, 00166 Rome, Italy
Author to whom correspondence should be addressed.
Cells 2019, 8(1), 49;
Received: 21 December 2018 / Revised: 7 January 2019 / Accepted: 9 January 2019 / Published: 14 January 2019
(This article belongs to the Special Issue Autophagy in Tissue Injury and Homeostasis)
Metformin has been shown to inhibit glutaminase (GLS) activity and ammonia accumulation thereby reducing the risk of hepatic encephalopathy in type 2 diabetic patients. Since tumour cells are addicted to glutamine and often show an overexpression of glutaminase, we hypothesize that the antitumoral mechanism of metformin could be ascribed to inhibition of GLS and reduction of ammonia and ammonia-induced autophagy. Our results show that, in different tumour cell lines, micromolar doses of metformin prevent cell growth by reducing glutamate, ammonia accumulation, autophagy markers such as MAP1LC3B-II and GABARAP as well as degradation of long-lived proteins. Reduced autophagy is then accompanied by increased BECN1/BCL2 binding and apoptotic cell death. Interestingly, GLS-silenced cells reproduce the effect of metformin treatment showing reduced MAP1LC3B-II and GABARAP as well as ammonia accumulation. Since metformin is used as adjuvant drug to increase the efficacy of cisplatin-based neoadjuvant chemotherapy, we co-treated tumour cells with micromolar doses of metformin in the presence of cisplatin observing a marked reduction of MAP1LC3B-II and an increase of caspase 3 cleavage. In conclusion, our work demonstrates that the anti-tumoral action of metformin is due to the inhibition of glutaminase and autophagy and could be used to improve the efficacy of chemotherapy. View Full-Text
Keywords: autophagy; cell death; glutaminase; metabolism; molecular rehabilitation. autophagy; cell death; glutaminase; metabolism; molecular rehabilitation.
Show Figures

Figure 1

MDPI and ACS Style

Saladini, S.; Aventaggiato, M.; Barreca, F.; Morgante, E.; Sansone, L.; Russo, M.A.; Tafani, M. Metformin Impairs Glutamine Metabolism and Autophagy in Tumour Cells. Cells 2019, 8, 49.

AMA Style

Saladini S, Aventaggiato M, Barreca F, Morgante E, Sansone L, Russo MA, Tafani M. Metformin Impairs Glutamine Metabolism and Autophagy in Tumour Cells. Cells. 2019; 8(1):49.

Chicago/Turabian Style

Saladini, Serena; Aventaggiato, Michele; Barreca, Federica; Morgante, Emanuela; Sansone, Luigi; Russo, Matteo A.; Tafani, Marco. 2019. "Metformin Impairs Glutamine Metabolism and Autophagy in Tumour Cells" Cells 8, no. 1: 49.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop